Compare ADMA Biologics Inc (ADMA) vs Amcor PLC (AMCR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Amcor PLC — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Amcor PLC trades at $41.89 (market cap $20.55B). The key difference: Amcor PLC is far larger — about 9.6× ADMA Biologics Inc's market cap, and Amcor PLC pays a 5.85% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | AMCR | |
|---|---|---|
Market Cap | $2.13B | $20.55B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $50.58 |
52-Week Low | $7.60 | $36.69 |
Enterprise Value | $2.20B | $35.67B |
Dividend Yield | — | 5.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
AMCR trades at $44.45, down 1.22% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported revenue of $15.01B in 2025, with net income of $511M, and has beaten EPS estimates for the last three quarters. Recent news highlights sustainable packaging partnerships and leadership changes aimed at growth.
The stock offers a moderate upside to the consensus price target of $45.75, supported by a 69% analyst buy rating, but faces risks from integration challenges post-Berry acquisition and a high P/E ratio of 35.84. Earnings growth and synergy realization are key catalysts for 2027 recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →
